$4.34
2.36% today
Nasdaq, Sep 24, 07:16 pm CET
ISIN
US00847G7051
Symbol
AGEN

Agenus Inc. Stock price

$4.44
+0.05 1.14% 1M
+2.80 170.73% 6M
+1.70 62.04% YTD
-0.86 16.23% 1Y
-37.36 89.38% 3Y
-79.76 94.73% 5Y
-113.12 96.22% 10Y
-625.56 99.30% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.16 3.48%
ISIN
US00847G7051
Symbol
AGEN
Industry

Key metrics

Basic
Market capitalization
$141.5m
Enterprise Value
$166.6m
Net debt
$25.1m
Cash
$9.5m
Shares outstanding
30.0m
Valuation (TTM | estimate)
P/E
negative | 19.5
P/S
1.4 | 0.9
EV/Sales
1.6 | 1.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-144.2%
Return on Equity
69.7%
ROCE
185.3%
ROIC
-
Debt/Equity
-0.1
Financials (TTM | estimate)
Revenue
$101.7m | $166.1m
EBITDA
$-78.5m | $-148.1m
EBIT
$-91.4m | $-28.6m
Net Income
$-165.7m | $6.8m
Free Cash Flow
$-127.9m
Growth (TTM | estimate)
Revenue
-36.3% | 60.5%
EBITDA
20.7% | -33.3%
EBIT
19.6% | 77.0%
Net Income
25.9% | 103.0%
Free Cash Flow
31.3%
Margin (TTM | estimate)
Gross
99.4%
EBITDA
-77.2% | -89.2%
EBIT
-89.9%
Net
-162.9% | 4.1%
Free Cash Flow
-125.7%
More
EPS
$-5.9
FCF per Share
$-4.3
Short interest
8.6%
Employees
316
Rev per Employee
$330.0k
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Agenus Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Agenus Inc. forecast:

Buy
78%
Hold
22%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
102 102
36% 36%
100%
- Direct Costs 0.64 0.64
19% 19%
1%
101 101
36% 36%
99%
- Selling and Administrative Expenses 69 69
6% 6%
68%
- Research and Development Expense 123 123
38% 38%
121%
-78 -78
21% 21%
-77%
- Depreciation and Amortization 13 13
12% 12%
13%
EBIT (Operating Income) EBIT -91 -91
20% 20%
-90%
Net Profit -166 -166
26% 26%
-163%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
15 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) under France's compassionate access (Accès compassionnel, or AAC) framework. The Fre...
Neutral
Business Wire
19 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Dr. Richard Goldberg, Chief Development Officer, and Dr. Robin Taylor, Chief Commerc...
Neutral
Seeking Alpha
27 days ago
Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 316
Founded 1994
Website agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today